Click here to read the latest top ASX cannabis stocks article.

The Australian cannabis market is offering investors a healthy dose of investment opportunities as the industry continues to expand in the country.


While the overall marijuana capital space has faced its fair share of volatility, which has affected Australian players as well, the emergent status of the sector in the country offers high upside in the long term for cannabis names attached to the Australian Securities Exchange (ASX).

Read along to find out about the top ASX cannabis stocks of 2019. All stock information and numbers were accurate as of December 16, 2019.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

1. Ecofibre (ASX:EOF)

Year-to-date gain: 51.18 percent; current share price: AU$2.57

First on the list of top ASX cannabis stocks is Ecofibre, a biotech company that is working on the development of hemp-derived items for human and pet consumption in the US and Australia. Its hemp offerings include products for the health and wellness markets.

In 2019, the company completed a variety of developments that are critical to its production pipeline. One of the biggest announcements for the company this year was its approval to the NASDAQ International Designation program. Thanks to this admission, the company has gained more access to US investors with over-the-counter options.

Ecofibre CEO Eric Wang said that since the company’s profile in the US is increasing, the international designation gives investors an easier way to follow its activities.

2. Althea Group Holdings (ASX:AGH)

Year-to-date gain: 29.63 percent; current share price: AU$0.35

Althea Group Holdings takes the concept of medical cannabis a step further with its work as a pharmaceutical-grade cannabis supplier. In addition to offering relief through accessible medical cannabis, the company is implementing components of the plant in the research for advanced drugs.

The company has steadily increased its reach across Australia, with its patient count nearing 4,000 at the end of 2019. Patients who are counted are those who have been prescribed Althea products.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

During an annual general meeting, Althea CEO Joshua Fegan told investors that the company holds enough capital to fund its future endeavors.

“Our goals for next year include reaching 10,000 patients in Australia, adding new products to our portfolio like we have just done with Althea CBD100 and continuing our expansion into the UK and Germany,” Fegan said.

3. Botanix Pharmaceuticals (ASX:BOT)

Year-to-date gain: 28.57 percent; current share price: AU$0.09

This pharmaceutical company has a focus on product development for dermatological conditions and offers treatments for acne, psoriasis, atopic dermatitis and other skin conditions in patients.

One of the company’s candidates, BTX 1503, progressed towards preparations for a Phase 3 clinical trial during 2019, which is a critical landmark.

The company received a boost for its business in the US after the US Drug Enforcement Administration told Purisys, a partner of Botanix, that synthetic cannabidiol (CBD) is not a controlled substance.

“This change in the regulation of synthetic CBD in the US will make a major difference to the speed of developing Botanic products and greatly reduces the risks and costs of clinical development,” Vince Ippolito, executive chairman and president of Botanix, said in a statement.

Don’t forget to follow us @INN_Australia for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) (“Curaleaf” or the “Company”) a leading international provider of consumer products in cannabis, today announced that it will report its financial and operating results for the first quarter ended March 31, 2021 after market close on May 10, 2021 .

Management will host a conference call and audio webcast that evening at 5:00 p.m. ET consisting of prepared remarks followed by a question and answer session related to the Company’s operational and financial highlights.

Keep reading... Show less

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two new stores, the Company’s 85 th and 86 th nationwide to commemorate the 50 th anniversary of 420, the holiday recognizing cannabis culture.

The new Florida dispensaries, the Company’s 80 th and 81 st in the state, located in Eustis and Palm Beach Gardens , further demonstrate Trulieve’s goal of ensuring direct, reliable access to medical cannabis across its home state.

Keep reading... Show less

CANBUD Distribution Corp. (CSE:CBDX, FSE:CD0) leverages on timely and methodical execution of its revenue generating plan. It operates a trinitarian enterprise model in the plant-based protein, psychedelic pharmaceutical and non-psychedelic nutraceutical, and hemp cannabinoids (CBD) spaces. (www.canbudcorp.com).

Keep reading... Show less

(TheNewswire)

Keep reading... Show less

Market entry will address pent-up demand in the Japanese & Philippine markets for TRACE proprietary plant-based mineral formulation and wellness-focused products

Emerging leader in innovative health and wellness beverages and natural products, BevCanna Enterprises Inc. ( CSE:BEV , Q:BVNNF , FSE:7BC ) (“ BevCanna ” or the “ Company ”) announces today that has entered into an exclusive sales agency distribution agreement with Yokohama-based Mirai Marketing Inc. (“Mirai”) to bring Naturo Group’s TRACE proprietary plant-based mineral consumer products to Mirai’s extensive Japanese and Philippine sales and distribution networks.

Keep reading... Show less